{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:44:56Z","timestamp":1790693096916,"version":"4.1.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,7,23]]},"DOI":"10.1001\/jama.2019.9055","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T13:31:19Z","timestamp":1564666279000},"page":"315","source":"Crossref","is-referenced-by-count":313,"title":["Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy"],"prefix":"10.1001","volume":"322","author":[{"given":"Mark C.","family":"Genovese","sequence":"first","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kalunian","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelufar","family":"Mozaffarian","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Matzkies","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tasset","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Sundy","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Walker","sequence":"additional","affiliation":[{"name":"Northumbria Healthcare, North Shields, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi190069r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"joi190069r2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"joi190069r3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"joi190069r4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects.","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"9","key":"joi190069r5","first-page":"1650","article-title":"The Jak-STAT pathway in rheumatoid arthritis.","volume":"32","author":"Walker","year":"2005","journal-title":"J Rheumatol"},{"issue":"11","key":"joi190069r6","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis.","volume":"118","author":"Brennan","year":"2008","journal-title":"J Clin Invest"},{"issue":"7","key":"joi190069r7","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"joi190069r8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"joi190069r9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"joi190069r10","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"joi190069r11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/(ISSN)1529-0131","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis.","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"1","key":"joi190069r13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.v38:1","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"2","key":"joi190069r14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Measurement of patient outcome in arthritis.","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"5","key":"joi190069r15","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"issue":"6","key":"joi190069r16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"joi190069r17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation.","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"joi190069r18","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"joi190069r19","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"joi190069r20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice.","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"10139","key":"joi190069r21","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"13","key":"joi190069r22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis.","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"9865","key":"joi190069r23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"joi190069r24","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/ar3249","article-title":"Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-a inhibitors.","volume":"13","author":"Rendas-Baum","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"joi190069r12","unstructured":"Disease Activity Score in rheumatoid arthritis. https:\/\/www.das-score.nl\/das28\/en\/introduction-menu.html. Accessed January 15, 2019."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/article-pdf\/322\/4\/315\/17730608\/jama_genovese_2019_oi_190069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T13:31:25Z","timestamp":1564666285000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2738551"}},"subtitle":["The FINCH 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7,23]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.9055","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,23]]}}}